Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on July 24, reiterating a Buy rating on the stock with an $850 price target.

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

The firm stated that it anticipates weakness to continue in EYLEA sales for Q2 2025, primarily because of biosimilar competition and continued co-pay assistance shortfalls.

Canaccord further said that it is on the lookout for updates from the pipeline (Factor XI, Obesity) to point to potential upside in the second half of 2025.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.